RxDoctor Payments Data

Michael Mendelsohn

Internal Medicine · Boston, MANPI 1851435549

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,550,315 of the $1,552,547 with a category attached, or 99.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $456,000 and has fallen 86.8% since, to $60,143 in 2024. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,552,547in general payments, 2019–2025

Across 96 payments — averaging $16,172 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1.5M
  • Ironwood Pharmaceuticals, Inc$31K
  • Takeda Pharmaceutical Company, Limited$22
$2,246,242in research payments, 2019–2025

Across 1 payment — averaging $2,246,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceutical Company, Limited$2.2M

What the payments were for

  • Consulting fees$1,550,315100%
  • Travel & lodging$2,0890%
  • Food & beverage$1430%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,552,547 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →